Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.

Professor Nicholas Turner has been recognised with a prestigious Fellowship of the Academy of Medical Sciences for his excellence in breast cancer research and outstanding contribution to the field.

A blood test to watch breast cancer’s ‘molecular clock’ could help track the growth of multiple tumours around the body and monitor how they are responding to treatment, new research suggests.